Japan aims to fast-track review of anti-viral drug remdesivir
Japan will fast-track a review of Gilead Sciences Inc’s antiviral drug remdesivir so that it can hopefully be approved for domestic COVID-19 patients a week after the U.S. firm’s filing for such approval, the health minister said on Saturday.
